JeanMarie Guenot: CEO of Amphivena Therapeutics Inc

 

JeanMarie Guenot is a distinguished professional in the biotechnology and pharmaceutical industry. She has provided her services to different enterprises, both in the public and sector, for over two decades. She has ample skills in venture capital and business development. Guenot also has substantial experience in pharmaceutical R&D, project and alliance management and corporate and commercial development. Over the two decades, she has gotten a strong passion for creating and redeveloping companies. At the moment, JeanMarie Guenot is the CEO and President of Amphivena Therapeutics, Inc. Together, they focus on the creation of innovative bi-functional antibody therapies for hematologic malignancies.

 

 

Career

 

 

Before her position at Amphivena, she was the President of SKS Ocular. Guenot founded this ophthalmic company, and it specialized on dry AMD. It was involved in the manufacturing and processing of therapeutics and ocular drug technologies for glaucoma, molecular degeneration, and ocular inflammation. In addition to that, JeanMarie served as a business advocate for Hoffman-La Roche in Shanghai and Basel. She was once the vice president of business and corporate development at PDL BioPharma. While working there, her primary roles were overseeing acquisitions and mergers, alliance management for the firm’s R&D and commercial product portfolios as well as licensing.

 

 

She negotiated and managed to close the Idec-PDL 50:50 deal. According to this deal, the two firms were to be involved in the developing and commercializing of a cancer drug. The coming together included three Phase-2 drug patients. It was an 800 million dollar transaction which encompassed 100 million dollar equity investment in PDL as well as therapeutic candidates. Biogen Idec and Hoffman-La Roche shared Ophthalmic which had been licensed by Guenot. She is highly skilled and experienced in ophthalmic diseases and auto-immune diseases.

 

 

JeanMarie Guenot’s career began at Atlas Venture. At the company, she managed venture capital investments and developed life science firms. Her scientific career began when she was appointed as the principal scientist at Hoffman-La Roche. Her role at the enterprise was developing drugs for metabolic and inflammation diseases. JeanMarie holds an MBA from the University of Pennsylvania and afterward got her Ph.D. from the University of California.

Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen

Arthur Becker Speaks On The Secrets Of His Success

Arthur Becker serves Madison Partners, LLC as the managing member. He has also served in other remarkable roles such as the chairman and chief executive officer of Zinio, LLC from 2012-2015. Zinio is the leading digital newsstand in the global market. Before his service at Zinio, Arthur Becker was the chief executive officer of NaviSite. NaviSite is a NASDAQ quoted organization that offers internet technology services, colocation to businesses and hosting in the United States and the United Kingdom from 2002 to 2010. They have their offices in India, the United States, and the United Kingdom. Arthur has also served the Vera Wang fashion company as the senior advisor for seven years. He has been a private investor in sectors such as technology as well as real estate since Time Warner acquired NaviSite.

Speaking in an interview with US Magazine, Arthur said that the idea of Madison Partners came after he chose to expand his interest in the real estate sector. This was after NaviSite was sold to Time Warner in 2011. To this end, he invested in condominium development in New York, Florida and Miami. He also said he became exposed to some early stage biotech companies, and that the evolving paradigms in the biotech, the combination of significant economic openings, and the ability to make a positive impact on people’s lives is what fascinated Arthur Becker.

Arthur describes himself as a man of great intrigue in various tech trends and specifically in the field of combating cancer. He says that he is exposed to some different approaches even though he lacks medical training. He acknowledges that as an entrepreneur, his greatest challenge was balancing passion, drive and critical thinking. The challenges facing startups is the mix of a clear vision, passion for engaging, unrelenting drive, proper leadership alongside the ability to critically judge how to adjust the vision, the strategy and at times the workforce.

He says in his ventures over the years, the successes and the failures are all valuable lessons for him. He says that his experienced has helped him to avoid similar failures going ahead. He has learned that the chemistry between management is always significant to the success of an operating business.